Market capitalization | €44.41m |
Enterprise Value | €39.54m |
P/E (TTM) P/E ratio | 7.72 |
EV/Sales (TTM) EV/Sales | 2.24 |
P/S ratio (TTM) P/S ratio | 2.52 |
P/B ratio (TTM) P/B ratio | 2.49 |
Dividend yield | 3.89% |
Last dividend (FY24) | €0.95 |
Revenue growth (TTM) Revenue growth | -5.59% |
As a Free StocksGuide user, you can view scores for all 6,891 stocks worldwide.
1 Analyst has issued a forecast MeVis Medical Solutions:
1 Analyst has issued a forecast MeVis Medical Solutions:
Mar '24 |
+/-
%
|
||
Revenue | 18 18 |
6%
6%
|
|
Gross Profit | 6.82 6.82 |
15%
15%
|
|
EBITDA | 4.38 4.38 |
24%
24%
|
EBIT (Operating Income) EBIT | 4.27 4.27 |
25%
25%
|
Net Profit | 5.75 5.75 |
7%
7%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MeVis Medical Solutions AG engages in the development of software for analyzing and evaluation image data for manufacturers of medical devices and providers of medical information technology platforms. It operates through Digital Mammography, Development Services and Other Operating Activities segments. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. The Development Services segment comprises the assignment of software development teams, i.e. software developers, product and project managers, application specialists and test engineers, for the contract development of software modules for external customers. The segment Other Operating Activities includes the lung, liver, neuro and MeVis Online Services product areas. The company was founded by Carl J.G. Evertsz and Heinz-Otto Peitgen in 1997 and is headquartered in Bremen, Germany.
Head office | Germany |
CEO | Marcus Kirchhoff |
Employees | 114 |
Founded | 1997 |
Website | www.mevis.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.